$25.36
-0.78%Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Strong net margins indicate efficient operations and favorable tax/interest management.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
PFE โข NYSE
| Pfizer Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
62.6B | 63.6B | 59.6B | 100.3B | 81.3B | 41.7B | 41.2B | 53.6B | 52.5B | 52.8B | 48.9B | 49.6B | 51.6B | 54.7B | 61B | 67.1B | 50B | 48.3B | 48.4B | 48.4B | |
GROSS PROFIT | ||||||||||||||||||||
(18.6B) | (21.8B) | (29.2B) | (38.2B) | (34.4B) | (11.8B) | (12.6B) | (16B) | (15.8B) | (16B) | (13.2B) | (13.3B) | (14B) | (14.6B) | (17.2B) | (20.7B) | (11.6B) | (10B) | (11.7B) | (10.5B) | |
44B | 41.8B | 30.3B | 62.1B | 46.9B | 29.9B | 28.5B | 37.6B | 36.8B | 36.9B | 35.7B | 36.3B | 37.6B | 40B | 43.9B | 46.3B | 38.4B | 38.3B | 36.7B | 37.9B | |
OPERATING INCOME | ||||||||||||||||||||
(28.6B) | (25.4B) | (25B) | (24.5B) | (26.1B) | (20.8B) | (21B) | (22.4B) | (22.4B) | (22.6B) | (22.4B) | (22.3B) | (20.7B) | (22B) | (25.5B) | (28.6B) | (22.4B) | (21.6B) | (22.8B) | (22.8B) | |
(13.3B) | (14.7B) | (14.5B) | (13.1B) | (12.3B) | (11.4B) | (12.7B) | (14.4B) | (14.7B) | (14.8B) | (14.7B) | (14B) | (14.2B) | (15B) | (17.5B) | (19.3B) | (14.7B) | (14.1B) | (15.2B) | (15.3B) | |
(12B) | (10.7B) | (10.6B) | (11.4B) | (13.8B) | (9.4B) | (8.4B) | (8B) | (7.6B) | (7.8B) | (7.7B) | (8.3B) | (6.6B) | (7B) | (8B) | (9.4B) | (7.8B) | (7.5B) | (7.6B) | (7.4B) | |
15.4B | 16.5B | 5.3B | 37.5B | 20.8B | 9.1B | 7.5B | 15.3B | 14.4B | 14.3B | 13.3B | 14B | 16.9B | 18B | 18.4B | 17.7B | 16B | 16.6B | 13.9B | 15.1B | |
PRE-TAX INCOME | ||||||||||||||||||||
(2.7B) | (3.1B) | (2.2B) | (1.2B) | (1.3B) | (1.4B) | (1.6B) | (1.3B) | (1.3B) | (1.2B) | (1.2B) | (1.4B) | (1.4B) | (1.5B) | (1.7B) | (1.8B) | (1.2B) | (516M) | (397M) | (488M) | |
-2.1B | -2.5B | -585M | -987M | -1.3B | -1.4B | -1.3B | -983M | -879M | -716M | -728M | -935M | -1B | -1.1B | -1.2B | -1.4B | -487M | 772M | 1.1B | 437M | |
(3.3B) | -105M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-7.9B | -8.5B | -4.2B | -2.8B | 3.5B | -2B | 4B | -3.4B | -2.1B | -5.9B | -4.3B | -1.8B | -1.2B | -6.8B | -6.9B | -8.5B | -5.2B | -6.9B | -4.6B | -2.1B | |
7.5B | 8B | 1.1B | 34.7B | 24.3B | 7B | 11.5B | 11.9B | 12.3B | 8.4B | 9B | 12.2B | 15.7B | 11.2B | 11.5B | 9.3B | 10.8B | 9.7B | 9.3B | 13B | |
NET INCOME | ||||||||||||||||||||
-266M | -28M | -1.1B | (3.3B) | (1.9B) | (370M) | (618M) | (706M) | -9B | (1.1B) | (2B) | (3.1B) | (4.3B) | (2.2B) | (3.6B) | (1.1B) | (2.2B) | (1.6B) | (1B) | (2B) | |
7.8B | 8B | 2.1B | 31.4B | 22.1B | 9.2B | 16.3B | 11.2B | 21.3B | 7.2B | 7B | 9.1B | 11.6B | 9.8B | 8.7B | 8.3B | 8.6B | 8B | 8.2B | 11B |
PFE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 12, 2026 | April 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 28, 2025 | 2025 |
Continue your PFE research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.